Market Overview

Genprex Provides Clinical and Corporate Update for Second Quarter 2018

Share:

Genprex,
Inc.
(NASDAQ:GNPX), a clinical stage gene therapy company developing
a new approach to treating cancer based upon a novel proprietary
technology platform, today announced a clinical and corporate update,
and the filing of quarterly results for the second quarter ended June
30, 2018 on Form 10-Q with the Securities and Exchange Commission.

Rodney Varner, Chairman and CEO, remarked, "We have made significant
progress in recent months to advance the development of Oncoprex™ for
treatment of non-small cell lung cancer (NSCLC), including engaging
collaborators with expertise and other resources necessary for important
pre-clinical and clinical services. We also obtained an additional $10
million in capital, which provides additional financial resources to
position the Company to achieve its critical milestones in its path
toward developing and commercializing Oncoprex. "

Julien L. Pham, MD, MPH, President and Chief Operating Officer, stated,
"We are moving toward resuming enrollment in the Phase I/II clinical
evaluating the combination of Oncoprex™ and erlotinib (Tarceva®) for the
treatment of Stage IV non-small cell lung cancer (NSCLC), adding an
additional preclinical trial to study Oncoprex in combination with
immunotherapies, and progressing with manufacturing scale-up."

Clinical Development Highlights (May 2018 to present)

  • Selected Accenture to provide clinical data management services to
    help accelerate the clinical development of Genprex's lead drug
    candidate, Oncoprex™.
  • Entered an agreement to use WIRB-Copernicus Group (WCG) to provide
    site selection and feasibility services, including Institutional
    Review Board (IRB) and Institutional Biosafety Committee (IBC)
    oversight for new clinical trial sites that Genprex anticipates adding
    to participate in its Phase I/II clinical trial evaluating the
    combination of OncoprexTM and erlotinib (Tarceva®) in NSCLC.
  • Selected 4Clinics as a CRO to provide clinical and regulatory support
    for the clinical development program in the form of biostatistics,
    statistical programming and analysis, as well as medical and
    scientific writing for the Phase I/II clinical trial.
  • Entered an agreement with The University of Texas MD Anderson Center
    under which Genprex is sponsoring a pre-clinical study intended to
    develop a novel therapeutic approach for the treatment of cancer using
    a combination of the multifactorial tumor suppressor gene TUSC2 and
    immunotherapy, including the immune checkpoint inhibitors anti-PD1
    and/or anti CTLA-4. This study will include the identification of
    biomarkers to predict the response to TUSC2-immunotherapy combinations.
  • Amended its agreement with The University of Texas MD Anderson Cancer
    Center to resume patient enrollment in its Phase I/II trial evaluating
    the combination of Oncoprex™ and erlotinib (Tarceva®) for the
    treatment of Stage IV non-small cell lung cancer (NSCLC).

Corporate Update

  • Entered an agreement with the University of Texas at Austin Dell
    Medical School to establish executive offices at the school's Health
    Discovery Building, joining the WorkSpaces @ Texas Health CoLab.
    WorkSpaces @ Texas Health CoLab is designed to identify and support
    people and companies that share Dell Medical School's commitment to
    improving health outcomes to patients and reducing healthcare costs.
  • Established offices in Cambridge, MA, where Dr. Julien Pham, President
    and COO will oversee the clinical development of Genprex's lead drug
    candidate, Oncoprex™.
  • Completed a $10 million private placement.

Forward Looking Statements

Statements contained in this press release that are not statements of
historical facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because these
statements are subject to risks and uncertainties, the actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements about Genprex's business plans, statements about the
timing and success of the Company's existing and planned clinical
trials, statements about the development of the Company's current and
potential future product candidates, statements about the Company's
plans to seek regulatory approval of its product candidates, and
statements about the services the Company expects to receive from its
development partners and the effect of those services on the development
of Oncoprex. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success, cost and timing of the
Company's product candidate development activities and current and
planned clinical trials; the Company's ability to execute on its
strategy; regulatory developments in the United States and foreign
countries; the Company's estimates regarding expenses, future revenue
and capital requirements; and the ability of the Company's development
partners to provide services to the Company and the Company's ability to
utilize those services, and the ability of those services to influence
the development of Oncoprex. These and other risks and uncertainties are
described more fully under the caption "Risk Factors" and elsewhere in
Genprex's filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in this
press release speak only as of the date on which they were made. Genprex
does not undertake any obligation to update these statements to reflect
any events that occur or facts that exist after the date on which the
statements were made.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new
approach to treating cancer, based upon a novel proprietary technology
platform, including Genprex's initial product candidate, Oncoprex™
immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's
platform technologies are designed to administer cancer fighting genes
by encapsulating them into nanoscale hollow spheres called nanovesicles,
which are then administered intravenously and taken up by tumor cells
where they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts cell
signaling pathways that cause replication and proliferation of cancer
cells, re-establishes pathways for apoptosis, or programmed cell death,
in cancer cells, and modulates the immune response against cancer cells.
Oncoprex has also been shown to block mechanisms that create drug
resistance. Visit the company's web site at www.genprex.com
or follow Genprex on Twitter at https://twitter.com/genprex
and Facebook at https://www.facebook.com/genprexinc/.

View Comments and Join the Discussion!